Hayat Umar, Ashfaq Muhammad Z, Haseeb Muhammad, Farhan Muhammad L, Kamal Muhammad Umar, Talib Khandokar A, Khan Hafiz M A, Siddiqui Ali A
Department of Internal Medicine, Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA.
Creighton University School of Medicine, Omaha, Nebraska.
J Clin Gastroenterol. 2024 Mar 1;58(3):297-306. doi: 10.1097/MCG.0000000000001851.
This metanalysis aims to assess the efficacy and safety of biliary stenting along with radiofrequency ablation compared with stents alone to treat malignant biliary obstruction (MBO) due to extrahepatic biliary strictures secondary to cholangiocarcinoma, pancreatic cancer, and metastatic cancer.
A systemic search of major databases through April 2022 was done. All original studies were included comparing radiofrequency ablation with stenting versus stenting alone for treating malignant biliary strictures. The primary outcomes of interest were the difference in the mean stent patency and overall survival (OS) days between the 2 groups. The secondary outcome was to compare the adverse events of the 2 groups. The mean difference in the stent patency and OS days was pooled by using a random-effect model. We calculated the odds ratio to compare the adverse events between the 2 groups.
A total of 13 studies with 1339 patients were identified. The pooled weighted mean difference in stent patency was 43.50 days (95% CI, 25.60-61.41), favoring the RFA plus stenting. Moreover, the pooled weighted mean difference in OS was 90.53 days (95% CI, 49.00-132.07), showing improved survival in the RFA group. Our analysis showed no statistically significant difference in adverse events between the 2 groups OR 1.13 (95% CI, 0.90-1.42).
Our analysis showed that RFA, along with stent, is safe and is associated with improved stent patency and overall patient survival in malignant biliary strictures. More robust prospective studies should assess this association further.
本荟萃分析旨在评估与单纯支架置入术相比,胆道支架置入联合射频消融术治疗胆管癌、胰腺癌和转移性癌继发的肝外胆管狭窄所致恶性胆道梗阻(MBO)的疗效和安全性。
对截至2022年4月的主要数据库进行系统检索。纳入所有比较射频消融联合支架置入术与单纯支架置入术治疗恶性胆道狭窄的原始研究。主要观察指标是两组之间平均支架通畅时间和总生存期(OS)天数的差异。次要观察指标是比较两组的不良事件。采用随机效应模型汇总支架通畅时间和OS天数的平均差异。我们计算比值比以比较两组之间的不良事件。
共纳入13项研究,涉及1339例患者。支架通畅时间的合并加权平均差异为43.50天(95%CI,25.60 - 61.41),支持射频消融联合支架置入术。此外,OS的合并加权平均差异为90.53天(95%CI,49.00 - 132.07),表明射频消融组生存期有所改善。我们的分析显示两组之间不良事件无统计学显著差异,比值比为1.13(95%CI,0.90 - 1.42)。
我们的分析表明,射频消融联合支架置入术是安全的,并且与恶性胆道狭窄患者支架通畅时间延长和总体生存期改善相关。更有力的前瞻性研究应进一步评估这种关联。